Strand V, Schiff M, Tundia N, et al. - Patient-reported outcomes (PROs) responses between upadacitinib 15 mg or 30 mg and placebo were assessed at week 12 from the SELECT-BEYOND trial in order to contrast upadacitinib, an oral, selective JAK-1 inhibitor, with placebo to evaluate clinically significant improvements in PROs in 498 people with RA who have had incomplete responses to biologic disease-modifying antirheumatic drugs (bDMARD-IR). It was discovered that in bDMARD-IR RA persons, upadacitinib (15 mg or 30 mg) enhanced various aspects of quality of life, and more individuals attained clinically important improvements addressing normative values in comparison with placebo.